Brief: Inhibikase Therapeutics Issues Letter To Shareholders And Provides Update On Development Programs
19/12/2023 13:33
Dec 19 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ISSUES LETTER TO SHAREHOLDERS AND
PROVIDES UPDATE ON DEVELOPMENT PROGRAMS
* INHIBIKASE THERAPEUTICS INC - WE PLAN TO SUBMIT
COMPLEMENTARY
REGULATORY DOCUMENTS FOR RISVODETINIB TO EUROPEAN UNION
AUTHORITIES IN 2024
Source text for Eikon: ID:nGNXZtKCb
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Appoints Scott Wasserman To Board Of Directors
Inhibikase Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Inhibikase Q2 net loss widens on higher R&D, SG&A costs
Inhibikase Therapeutics, Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share